The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.

The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.

It has been discovered that the cyclic peptide EnnA inactivates the Hsp90 chaperone pathway, but without activating an extensive heat shock response and overexpression of anti-apoptotic proteins. Mechanistically distinct, EnnA inhibits Hsp90 and destabilize PDL-1 and IDO, two major immune checkpoints mediating tumor-induced immune suppression. The provided herein show that EnnA profoundly modulates the cytokine signature of cancer cells and promotes a cytokine profile that favors an immune attack on tumor cells. This translates into highly efficacious anti-tumor activity in vivo, which, when combined with a single dose of chemotherapy, completely reduced the tumor burden in experimental animals and instilled highly efficient immune memory against the primary tumor.

It has been discovered that the cyclic peptide EnnA inactivates the Hsp90 chaperone pathway, but without activating an extensive heat shock response and overexpression of anti-apoptotic proteins. Mechanistically distinct, EnnA inhibits Hsp90 and destabilize PDL-1 and IDO, two major immune checkpoints mediating tumor-induced immune suppression. The provided herein show that EnnA profoundly modulates the cytokine signature of cancer cells and promotes a cytokine profile that favors an immune attack on tumor cells. This translates into highly efficacious anti-tumor activity in vivo, which, when combined with a single dose of chemotherapy, completely reduced the tumor burden in experimental animals and instilled highly efficient immune memory against the primary tumor.

A NAB815 compound having the following formula (I), wherein: L is OA, R1 is -Dab, R2 is -Thr, R3 is -DThr, R4 is -Dab, R5 is -Dab, R6 is -DPhe, R7 is -Leu, R8 is -Abu, R9 is -Dab, R10 is -Thr, or a pharmaceutically acceptable salt thereof is provided for a use in the treatment and/or the prevention of the hemolytic-uremic syndrome.

##STR00001##

A NAB815 compound having the following formula (I), wherein: L is OA, R1 is -Dab, R2 is -Thr, R3 is -DThr, R4 is -Dab, R5 is -Dab, R6 is -DPhe, R7 is -Leu, R8 is -Abu, R9 is -Dab, R10 is -Thr, or a pharmaceutically acceptable salt thereof is provided for a use in the treatment and/or the prevention of the hemolytic-uremic syndrome.

##STR00001##

The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.

The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.

Provided herein are methods and compositions for treating solid tumor cancers.

Provided herein are hemoglobin-based therapeutic agents useful for treating cancer, pharmaceutical composition including the same, and methods of use and preparation thereof.